The team will have a closer look at therapy resistance in glioblastoma. They propose
to attack glioblastoma heterogeneity by rewiring the metabolism of macrophages
in the tumor micro-environment as well as the tumor cells directly. The team
will target metabolic vulnerabilities using novel nanoparticle tools to cross the
blood-brain barrier. This facilitated drug delivery is expected to render tumor
cells more susceptible to specific combination therapies, tailored to each
glioblastoma patient specifically. The teams will use complementary model systems (zebrafish, mouse, and human) and innovative chemistryto uncover precise mechanistic insights of glioblastoma malignancy with an outlook to create a translational path to patients.
NWO-XL consortium to develop new therapeutic concepts in glioblastoma treatment
For more information contact Bart Westerman.
Text and consortium image by Bart Westerman.